LONDON, May 9, 2014 /PRNewswire/ --
The markets on Thursday, May 08, 2014 ended on a mixed note as the S&P 500 finished the session 0.14% lower at 1,875.63, and the NASDAQ Composite closed at 4,051.50, down 0.40%. The Dow Jones Industrial Average finished at 16,550.97, up 0.20%. During the session, the five out of ten sectors ended in positive. The session saw a positive impact from Telecommunication Services, Consumer Discretionary and Financials sectors along with a drag from Energy, Utilities and Health Care sectors. The S&P 500 Health Care Sector Index closed the day at 664.48, down 0.53%, while the index has advanced 1.96% in the previous three months. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Clovis Oncology Inc. (NASDAQ: CLVS) and Sangamo BioSciences Inc. (NASDAQ: SGMO). Free technical research on ALXN, ACOR, CLVS and SGMO can be downloaded upon signing up at:
Alexion Pharmaceuticals Inc.'s stock declined 1.71%, to close the day at $151.05. The stock recorded a trading volume of 1.04 million shares, much below its three months average volume of 1.89 million shares. The stock oscillated between $150.68 and $157.07 during the session. Although, Alexion Pharmaceuticals Inc. stock has lost 5.42% in the previous three trading sessions, it has advanced 2.30% in the last one month and 13.67% since the start of this year. The stock is trading above its 200-day moving average of $133.98, while the 200-day moving average is below Alexion Pharmaceuticals Inc.'s 50-day moving average of $159.98. Additionally, the stock traded at a PE ratio of 71.03 and has an RSI of 48.56. Sign up today to read free research on ALXN at:
Acorda Therapeutics Inc.'s stock finished the Thursday's session 3.45% lower at $29.69. A total of 0.48 million shares were traded, which was close to its three months average volume of 0.53 million shares. The stock moved between $29.61 and $31.23 during the session. Shares of the company traded at a PE ratio of 65.42. Over the previous three trading sessions and the last three months, Acorda Therapeutics Inc.'s shares have declined 6.43% and 1.69%, respectively. However, from the beginning of 2014, the company's stock has gained an upside of 1.68%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $36.56 is greater than its 200-day moving average of $33.99. Acorda Therapeutics Inc.'s stock has an RSI of 33.09. Sign up today to read free research on ACOR at:
On Thursday, shares in Clovis Oncology Inc. traded between $49.14 and $51.50 before ending the session 3.09% lower at $49.32. Clovis Oncology Inc.'s stock reported a trading volume of 0.69 million shares, which was above its three months average volume of 0.61 million shares. Clovis Oncology Inc.'s shares have declined 8.28% in the previous three trading sessions, 24.74% in the last one month and 18.17% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $68.85 and $64.40, respectively. Moreover, shares of the company have an RSI of 30.87. Sign up today to read free research on CLVS at:
On Thursday, shares in Sangamo BioSciences Inc. recorded a trading volume of 1.23 million shares, lower than its three months average volume of 1.62 million shares. The stock ended the day at $11.71, which was 0.43% below its previous day's closing of $11.76, and registered an intraday range of $11.64 and $12.72. Over the previous three trading sessions and over the last one month, company's shares have plummeted 11.76% and 24.65% respectively. Additionally, the stock has declined 15.69% since start of this year. The company's stock is trading below its 50-day and 200-day moving averages of $17.54 and $13.95, respectively. Furthermore, shares of the company have an RSI of 25.48. Sign up today to read free research on SGMO at:
=============== EDITOR'S NOTES: ===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.